CD33 CAR T-cells 비교 | 바이오정보모아

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

프로그램 선택

Overview Toxicology Clinical

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목	CGTStandard DatabasestalePhase 1 CD33 CAR T-cells (CD33 CAR T-cells) Zhejiang University·CD33 1 trials

Overview Program	CD33 CAR T-cells
Overview Company	Zhejiang University
Overview Modality	CGT
Overview Target	CD33
Overview Indication	Acute Myeloid Leukemia
Overview Phase	PHASE_1
Overview Status	RECRUITING
Overview Content status	Standard Database
Overview Data Confidence	Data Confidence · Medium
Overview Development Signal	Development Signal · Watch
Overview Approval status	Investigational

Toxicology Major finding	Nanobody-Engineered CLL-1 CAR T Cells: Optimizing Tumor-Specific Cytotoxicity and Minimizing Off-Tumor Toxicity.. Acute myeloid leukemia (AML) is an aggressive hematologic malignancy characterized by the rapid expansion of undifferentiated myeloid progenitors, leading to impaired hematopoiesis and poor patient prognosis. Although chimeric antigen receptor (CAR) T-cell therapy using single-chain va…
Toxicology CRS	Reported

Clinical Safety signal	Nanobody-Engineered CLL-1 CAR T Cells: Optimizing Tumor-Specific Cytotoxicity and Minimizing Off-Tumor Toxicity.. Acute myeloid leukemia (AML) is an aggressive hematologic malignancy characterized by the rapid expansion of undifferentiated myeloid progenitors, leading to impaired hematopoiesis and poor patient prognosis. Although chimeric antigen receptor (CAR) T-cell therapy using single-chain va…
Clinical Program phase	PHASE_1

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

프로그램 선택

Overview Toxicology Clinical

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목	CGTStandard DatabasestalePhase 1 CD33 CAR T-cells (CD33 CAR T-cells) Zhejiang University·CD33 1 trials

Overview Program	CD33 CAR T-cells
Overview Company	Zhejiang University
Overview Modality	CGT
Overview Target	CD33
Overview Indication	Acute Myeloid Leukemia
Overview Phase	PHASE_1
Overview Status	RECRUITING
Overview Content status	Standard Database
Overview Data Confidence	Data Confidence · Medium
Overview Development Signal	Development Signal · Watch
Overview Approval status	Investigational

Toxicology Major finding	Nanobody-Engineered CLL-1 CAR T Cells: Optimizing Tumor-Specific Cytotoxicity and Minimizing Off-Tumor Toxicity.. Acute myeloid leukemia (AML) is an aggressive hematologic malignancy characterized by the rapid expansion of undifferentiated myeloid progenitors, leading to impaired hematopoiesis and poor patient prognosis. Although chimeric antigen receptor (CAR) T-cell therapy using single-chain va…
Toxicology CRS	Reported

Clinical Safety signal	Nanobody-Engineered CLL-1 CAR T Cells: Optimizing Tumor-Specific Cytotoxicity and Minimizing Off-Tumor Toxicity.. Acute myeloid leukemia (AML) is an aggressive hematologic malignancy characterized by the rapid expansion of undifferentiated myeloid progenitors, leading to impaired hematopoiesis and poor patient prognosis. Although chimeric antigen receptor (CAR) T-cell therapy using single-chain va…
Clinical Program phase	PHASE_1